Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. registered for resale up to 6,589,796 ordinary shares represented by 3,294,898 ADSs, issuable upon exercise of warrants held by selling shareholders. The selling shareholders may not sell until the registration statement becomes effective.
Can-Fite will receive no proceeds from the selling shareholders’ resales; those proceeds go to the selling shareholders. Can-Fite may receive proceeds from warrants exercised for cash. If all warrants described are exercised for cash in full, proceeds would be approximately $8.31 million, which Can-Fite intends to use for research and development, general and administrative expenses, and working capital. Can-Fite had 6,063,093 ordinary shares outstanding as of September 25, 2026, a separate figure from the registered resale amount.
Can-Fite BioPharma Ltd. filed Amendment No. 1 to its Form F-3 registration statement solely to file an updated Exhibit 107 filing-fee table and restate the exhibit index. The amendment states that it does not modify any provision of the prospectus.
Can-Fite BioPharma Ltd. (CANF) filed a Form D for a Regulation D, Rule 506(b) exempt offering involving warrants. The notice covers investor warrants for 3,183,476 shares at $2.50 per share and placement agent warrants for 111,422 shares at $3.125 per share. The stated total offering amount is $8,306,884, which equals the aggregate exercise price of these new warrants if exercised in full. H.C. Wainwright & Co., LLC is the placement agent and is entitled to a 7% cash fee and 1% management fee on warrant exercise proceeds, plus $25,000 in non-accountable and $50,000 in accountable expenses. Can-Fite expects to use any proceeds for research and development, clinical trials, and other working capital and general corporate purposes, and states that no proceeds are expected to be paid to executive officers, directors or promoters.
Can-Fite BioPharma Ltd. (CANF) reports a peer-reviewed case describing a patient with advanced decompensated liver cirrhosis treated with its drug candidate Namodenoson, who showed resolution of ascites, regression of esophageal varices, and remained clinically stable for approximately 28 months before a successful liver transplant in January 2026. The treating physician noted that improvements in portal-hypertension complications occurred despite continued deterioration in hepatic synthetic function and viewed the case as supporting further evaluation of Namodenoson in advanced liver disease. Namodenoson, an A3 adenosine receptor agonist, is already in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial for MASH, and has Orphan Drug Designation in the U.S. and Europe and Fast Track status from the FDA for second-line HCC.
Can-Fite BioPharma Ltd. (CANF) is filing a post‑effective amendment on Form F‑1 to update and combine prior registration statements for the resale of 67,880 ordinary shares represented by 33,940 ADSs, all issuable upon exercise of placement agent warrants from its January 2023 and July 2025 financings. The filing covers only shares underlying warrants that remain unexercised and states that no additional securities are being registered beyond those in the prior registration statements and all related filing fees were previously paid. The company will not receive proceeds from selling shareholders’ resales, but may receive up to approximately $0.7 million from cash exercises of January 2023 placement agent warrants and approximately $0.4 million from cash exercises of remaining July 2025 warrants, which it currently plans to use for research and development, general and administrative expenses, and working capital. Ordinary shares outstanding were 6,063,093 as of September 6, 2026; this is a baseline figure, not the amount being offered.
Can-Fite BioPharma Ltd. (CANF) filed a post-effective amendment on Form F-1 that combines and updates two prior resale registration statements, covering up to 67,880 ordinary shares represented by 33,940 ADSs issuable upon exercise of placement agent warrants from its January 2023 and July 2025 financings. The registered securities are being offered for resale by existing selling shareholders; no ADSs are being sold by Can‑Fite itself.
Can‑Fite will not receive proceeds from any resale, but may receive up to roughly $0.7 million from January 2023-related warrants and $0.4 million from July 2025 warrants if they are exercised for cash. As of September 6, 2026, 6,063,093 ordinary shares were outstanding, with significant additional ordinary shares underlying options and warrants, indicating a sizable potential equity overhang. The prospectus highlights elevated dilution and market‑price pressure risk from warrant exercises and resales, and details extensive geopolitical risks tied to operating from Israel.
Can-Fite BioPharma Ltd. (CANF) reported first-half 2026 results showing continued clinical progress alongside ongoing losses and a modest cash base. For the six months ended June 30, 2026, revenues were $0.20 million, research and development expenses rose to $3.46 million, general and administrative expenses fell to $1.43 million, and net loss was $4.60 million versus $4.88 million a year earlier.
As of June 30, 2026, Can-Fite held $7.03 million in cash, cash equivalents and short-term deposits and had an accumulated deficit of about $180.8 million. Operating cash outflow was $5.31 million in the period. Management evaluated going-concern conditions and, based on cost-control and reprioritization plans, concluded these actions alleviate substantial doubt for at least 12 months, while still expecting the need for significant additional financing to advance its pipeline.
Clinically, Namodenoson’s Phase IIa pancreatic cancer study achieved its primary safety endpoint with durable survival outcomes, and a Phase IIb chemo-combination protocol is in development. In advanced hepatocellular carcinoma, blinded overall survival in the pivotal Phase III Namodenoson study appears longer than originally anticipated, prompting consideration of an earlier interim analysis. Piclidenoson’s pivotal Phase 3 psoriasis trial has reached its pre-specified interim analysis stage, with results expected in early 2027. Can-Fite also expanded patent coverage for Namodenoson and Piclidenoson in multiple territories and completed warrant-inducement transactions in March and September 2026 providing approximately $8 million in gross proceeds.
Can-Fite BioPharma Ltd. (CANF) entered into an inducement agreement with an existing warrant holder, who agreed to exercise for cash 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, instead of the original $5.00, in exchange for new warrants.
The company expects approximately $4.0 million in gross proceeds, before a 7.0% placement fee, a 1.0% management fee, and additional fixed expenses. In consideration, Can-Fite will issue new warrants for up to 3,183,476 ADSs at $2.50 per ADS and Placement Agent Warrants for 111,422 ADSs at $3.125 per ADS, all privately placed under a Section 4(a)(2) exemption.
The new and Placement Agent Warrants are immediately exercisable for two years from the effective date of a resale registration statement that Can-Fite plans to file and seek to have declared effective within 90 days. The company agreed to a 30‑day restriction on most new equity issuances and registrations and a one‑year restriction on Variable Rate Transactions, and intends to use net proceeds for research and development, clinical trials, and general corporate purposes.